Eugia US Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Eugia US Llc Pharmaceutical Import Records from India — 27 Products, $66.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eugia US Llc — Pharmaceutical Importer Profile (2026) | 27 Products, $66.2M Trade | TransData Nexus

Eugia US Llc

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $66.2M Total Trade · DGFT Verified

Eugia US Llc is a pharmaceutical importer based in United States with a total trade value of $66.2M across 27 products in 13 therapeutic categories. Based on 1,331 verified import shipments from Indian Customs (DGFT) records, Eugia US Llc is the #1 buyer in 4 products including Ertapenem, Piperacillin, Bortezomib. Eugia US Llc sources from 4 verified Indian suppliers, with Eugia Pharma Specialities Limited accounting for 95.3% of imports.

Eugia US Llc — Import Portfolio & Supplier Network

Eugia US Llc import network — 27 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eugia US Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Eugia Pharma Specialities Limited	$121.6M	2,744	95.3%
Aurobindo Pharma Limited	$5.6M	129	4.4%
Gland Pharma Limited	$373.7K

What Formulations Does Eugia US Llc Import?

Formulation	Value	Ships
Pantoprazole sodium for injection 40 MG	$2.7M	55
Dexamethasone sodium phosphate	$1.5M	33
Ertapenem for injection 1	$1.3M	25
Pantoprazole sodium for injection 40	$1.2M	25
Ertapenem for injection 1	$1.1M	22
Meropenem for injection 1 g/vial	$1.1M	21
Bupivacaine hydrochloride injection	$869.0K	20
Piperacillin & tazobactam for	$850.0K	17
Lidocaine hydrochloride USP, 1%	$768.9K	19
Medroxyprogesterone acetate	$700.0K	14
Rocuronium bromide injection 100MG/10ML	$690.5K	14
Triamcinolone acetonide injectable	$671.9K	26
Testosterone cypionate injection 200 MG/ML (testosterone cypionate injection usp200mg/vial-1ML - us	$600.0K	12
Progesterone injection 500MG/vial-10ML	$599.5K	12
Linezolid injection 600MG/300ML (2MG/ML)	$558.9K	12

Eugia US Llc imports 1,954 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 27 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ertapenem	Advanced Antibiotics	$12.4M	248	5.1%	1
2	Pantoprazole	Gastrointestinal	$7.7M	154	0.6%	4
3	Meropenem	Advanced Antibiotics	$6.3M	125	1.8%	3
4	Piperacillin	Advanced Antibiotics	$5.7M	114	4.3%	1
5	Sodium	Nutritional Supplements	$4.5M	91	1.3%	3
6	Acetaminophen	Analgesics & Antipyretics	$3.1M	65	1.3%	9
7	Amino	Nutritional Supplements	$3.1M	65	1.0%	13
8	Dexamethasone	Corticosteroids	$2.9M	58	1.3%	12
9	Carboplatin	Oncology	$2.8M	56	2.1%	2
10	Linezolid	Advanced Antibiotics	$2.8M	55	5.7%	3
11	Acyclovir	Antivirals	$2.1M	43	1.1%	10
12	Azithromycin	Antibiotics	$1.7M	34	0.9%	11
13	Methylprednisolone	Corticosteroids	$1.6M	32	4.1%	3
14	Vancomycin	Antibiotics	$1.4M	29	0.9%	4
15	Irinotecan	Oncology	$1.3M	25	1.6%	8
16	Prednisolone	Respiratory	$1.2M	24	1.2%	8
17	Bortezomib	Advanced Oncology	$1.1M	22	3.0%	1
18	Cyclophosphamide	Oncology	$950.0K	19	2.8%	2
19	Pemetrexed	Advanced Oncology	$800.0K	16	1.6%	3
20	Syringe	Medical Devices & Diagnostics	$600.0K	12	0.3%	16
21	Diltiazem	Cardiovascular	$550.0K	11	2.5%	9
22	Gentamicin	Antibiotics	$500.0K	10	1.0%	9
23	Mitomycin	Advanced Oncology	$329.1K	8	3.0%	6
24	Actinomycin	Advanced Oncology	$250.0K	5	5.1%	1
25	Verapamil	Cardiovascular	$250.0K	5	0.2%	18
26	Tobramycin	Antibiotics	$150.0K	3	0.4%	12
27	Posaconazole	Advanced Antifungals	$100.0K	2	0.1%	6

Eugia US Llc imports 27 pharmaceutical products across 13 categories into United States totaling $66.2M. The company is the #1 buyer for 4 products: Ertapenem, Piperacillin, Bortezomib, Actinomycin.

Eugia US Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eugia US LLC is an independent specialty pharmaceutical company headquartered in East Windsor, New Jersey. Established in 2023, the company focuses on delivering generic sterile injectables, oncology, hormones, and ophthalmic medicines. Eugia US operates as a pharmaceutical importer and distributor, sourcing finished pharmaceutical formulations from India to supply the U.S. market. Their product portfolio includes antibiotics, antivirals, respiratory, hematology, cardiovascular, and central nervous system medications, among others.

The company's mission is to provide high-quality products, competitive pricing, and consistent supply to institutional settings such as acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics. Eugia US emphasizes customer-centric values, offering customized product procurement solutions, fair pricing models, and fulfillment of drop shipment agreements. Their vertically integrated operations control critical processes like supply chain, distribution, and product quality, ensuring a consistent supply of high-quality products at reasonable prices.

2Distribution Network

Eugia US LLC's distribution network is centered around its headquarters at 279 Princeton Hightstown Road, East Windsor, NJ 08520. The company imports finished pharmaceutical formulations from India, with a significant portion of shipments arriving at major U.S. ports, including Newark, New Jersey, and New York, New York. For instance, on March 4, 2026, Eugia US received shipments at the Port of Newark, and on March 5, 2026, at the Port of New York.

While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Eugia US's strategic positioning in East Windsor, New Jersey, provides advantageous access to key transportation routes and proximity to major ports, facilitating efficient distribution across the United States.

3Industry Role

Eugia US LLC operates as a pharmaceutical importer and distributor within the U.S. market. By sourcing finished pharmaceutical formulations from India, the company plays a crucial role in enhancing the availability of generic injectable medications in the United States. Their focus on high-quality products and customer-centric services positions them as a significant player in the pharmaceutical supply chain, catering to various institutional settings and contributing to the overall healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eugia US Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eugia US LLC's sourcing strategy exhibits a high degree of concentration, primarily importing finished pharmaceutical formulations from four Indian suppliers:

EUGIA PHARMA SPECIALITIES LIMITED: $121.6 million (95.3% of total imports)
AUROBINDO PHARMA LIMITED: $5.6 million (4.4% of total imports)
GLAND PHARMA LIMITED: $374,000 (0.3% of total imports)
EUGIA STERILES PRIVATE LIMITED: $70,000 (0.1% of total imports)

This concentration indicates a strategic choice to maintain strong, reliable relationships with key suppliers, ensuring consistent product quality and supply. The substantial share of imports from EUGIA PHARMA SPECIALITIES LIMITED suggests a particularly close partnership, likely facilitating favorable terms and prioritization. However, such dependency also introduces risks related to supply chain disruptions or changes in supplier dynamics. The relatively small shares from other suppliers may serve as contingency options, providing some level of diversification without significantly altering the primary sourcing strategy.

Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing pharmaceutical imports, ensuring that all imported drugs meet the required safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and monitoring the safety of existing drugs. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the brand-name counterpart.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent, necessitating that all imported drugs be approved by the FDA. Manufacturers must comply with Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal recognition system for foreign GMP certifications, compliance with internationally recognized standards such as EU GMP, WHO GMP, or PIC/S can facilitate the approval process. Indian exporters seeking to supply Eugia US LLC and the U.S. market must ensure their manufacturing facilities adhere to these GMP standards and obtain the necessary FDA approvals for their products.

Eugia US Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eugia US LLC's product strategy focuses on therapeutic areas with high demand and potential shortages, including advanced antibiotics, gastrointestinal medications, and nutritional supplements. The company's top five imported products—Ertapenem, Meropenem, Piperacillin, Pantoprazole, and Sodium—align with this strategy, addressing critical needs in the U.S. healthcare system. By targeting these specific therapeutic areas, Eugia US aims to provide essential medications that are foundational to ensuring good health for millions of people.

2Sourcing Profile

Eugia US LLC's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on generic injectables. The company maintains a concentrated supplier base, primarily sourcing from EUGIA PHARMA SPECIALITIES LIMITED, with additional imports from AUROBINDO PHARMA LIMITED, GLAND PHARMA LIMITED, and EUGIA STERILES PRIVATE LIMITED. This approach allows Eugia US to leverage strong supplier relationships and ensure consistent product quality and supply. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a strategic sourcing partner for Eugia US.

3Market Positioning

Frequently Asked Questions — Eugia US Llc

What products does Eugia US Llc import from India?

Eugia US Llc imports 27 pharmaceutical products across 13 categories. Top imports: Ertapenem ($12.4M), Pantoprazole ($7.7M), Meropenem ($6.3M), Piperacillin ($5.7M), Sodium ($4.5M).

Who supplies pharmaceuticals to Eugia US Llc from India?

Eugia US Llc sources from 4 verified Indian suppliers. The primary supplier is Eugia Pharma Specialities Limited (95.3% of imports, $121.6M).

What is Eugia US Llc's total pharmaceutical import value?

Eugia US Llc's total pharmaceutical import value from India is $66.2M, based on 1,331 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eugia US Llc focus on?

Eugia US Llc imports across 13 categories. The largest: Advanced Antibiotics (40.9%), Gastrointestinal (11.6%), Nutritional Supplements (11.6%).

Get Full Eugia US Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.